Opinion|Videos|July 8, 2024
Emerging Pathways and Role of TROP2-Directed ADCs in HR+/HER2- mBC
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Medical oncologists provide insights on emerging pathways and TROP2-directed antibody-drug conjugates in HR+/HER2- metastatic breast cancer, highlighting ongoing research.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please comment on emerging pathways and how they might impact the future treatment landscape for patients with HR+/HER2-negative metastatic breast cancer.
Advertisement
Related to this article
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5